期刊
MABS
卷 13, 期 1, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2021.1967714
关键词
Bispecific; CrossMab; Immunotherapy; Oncology; Ophthalmology; TCB; T cell engager
CrossMab technology, introduced in 2011, enables correct light-chain and heavy-chain association in bispecific antibodies and has become one of the most mature and widely applied technologies in the field. Multiple bispecific antibodies based on CrossMab technology have entered clinical trials, demonstrating potential therapeutic value in different disease settings.
Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with methods enabling correct heavy-chain association using existing pairs of antibodies. Since the original description, CrossMab technology has evolved in the past decade into one of the most mature, versatile, and broadly applied technologies in the field, and nearly 20 bispecific antibodies based on CrossMab technology developed by Roche and others have entered clinical trials. The most advanced of these are the Ang-2/VEGF bispecific antibody faricimab, currently undergoing regulatory review, and the CD20/CD3 T cell bispecific antibody glofitamab, currently in pivotal Phase 3 trials. In this review, we introduce the principles of CrossMab technology, including its application for the generation of bi-/multispecific antibodies with different geometries and mechanisms of action, and provide an overview of CrossMab-based therapeutics in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据